Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VVUS: VIVUS INC. (NASDAQ) -- Ignore unavailable to you. Want to Upgrade?

To: DaiS who wrote (9248)	6/5/1998 6:35:00 PM
From: Zebra 365	Respond to of 23519

VIVUS INC (VVUS) 7 15/16 +1 5/8 (+25.7%). Investors are responding favorably to the erectile dysfunction treatment company's defense of the efficacy of its MUSE product. Earlier this week, a report presented at the American Urological Association conference suggested that MUSE was ineffective in most men when taken in a clinic environment, and less effective when used at home, with only 27% of patients using MUSE achieving an erection. The combination of that report and news released by the company that MUSE sales have fallen by two-thirds since Viagra's release, have sent VVUS shares tumbling from the $8.75 a share level. However, in a statement released today, Vivus is arguing that the presenting physician at the American Urological Association conference clarified that not all men were challenged to the highest doses (500 or 1000 mcg) of MUSE, and that only 10 of these 115 patients (or 9%) were administered the 1000 mcg dose. In VIVUS' clinical trials of MUSE, between 41% and 65% of men required the 1000 mcg dose to achieve rigidity sufficient for intercourse. The "Efficacy of MUSE is clearly dose dependent," stated Tom Lue, MD, Professor of Urology, University of California, San Francisco. "In my clinical practice, most patients require dosing of MUSE at the 500 or 1000 mcg level." Vivus' argument that its product was not given a fair shake by the researchers presenting data of the flaccid response rates has helped lift the stock 17% this morning in very active trading. The shares are also being assisted by news the company's CEO will be interviewed on CNBC Monday morning. Zebra

To: DaiS who wrote (9248)	6/5/1998 6:58:00 PM
From: alan laValley	Respond to of 23519

Am I missing something here? All this talk about contacting Vivus and #'s from clinical study, has anybody noticed the closing price 7 15/16 Yahoo ( woops another stock).... Anyway, this is a day to remember, easing some pressure on us margin wackos means sleep for the weekend...wow..wow.. What's bothering me about todays efforts is.......Why? I doubt what Leland had printed this morning had any effect on todays performance.... OK maybe I'm wrong but his credibility isn't exactly earth shaking. Could it then be the ....SEC...? Maybe the word is out and someone is finally going to be held accountable. Woops I'm jumping the gun here...guilty before trial... Would like others opinion as to why the stock movement.....other than squeezing the shorts...I don't believe this had anything to do with todays action.....